至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway

Front Mol Biosci. 2021-10; 
Yong Luo, Xiaobing Yang, Spyridon P Basourakos, Xuemei Zuo, Dechao Wei, Jiahui Zhao, Mingchuan Li, Qiankun Li, Tao Feng, Pengju Guo, Yongguang Jiang
Products/Services Used Details Operation
Plasmid DNA Preparation … JAK2 (clone ID: OHu24049, GenScript), the STAT1 (clone ID: OHu15845, GenScript) plasmid, and the control vector were transfected into cells using X-tremeGENE HP DNA transfection reagent (Roche). All samples were prepared 72 h after plasmid transfection for western … Get A Quote

摘要

Previous studies showed that CXCR7 expression was upregulated after enzalutamide (ENZ) treatment, and an increased level of CXCR7 could increase the invasion, migration, and angiogenesis of castration-resistant prostate cancer (CRPC) cells. This study demonstrated that the levels of p-JAK2, p-STAT1, C-Myc, and VEGFR2 were significantly reduced after CCX771, a specific CXCR7 inhibitor, treatment. This effect further increased after the combination treatment of ENZ and CCX771. Then, we verified that targeting the inhibition of JAK2 or STAT1 could remarkably increase apoptosis and DNA damage and decrease the migration of CRPC cells. More importantly, the combination treatment of ENZ + JAK2/STAT1 led to much greate... More

关键词

CXCR7, JAK2, STAT1, castration-resistant prostate cancer, enzalutamide, resistance